Technical Analysis for ORMP - Oramed Pharmaceuticals Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Lower Bollinger Band Walk | Weakness | -1.74% | |
| Lower Bollinger Band Touch | Weakness | -1.74% | |
| Expansion Breakdown | Bearish Swing Setup | 4.15% | |
| Below Lower BB | Weakness | 4.15% |
| Alert | Time |
|---|---|
| Possible NR7 | about 18 hours ago |
| Possible Inside Day | about 18 hours ago |
| Gap Down Closed | about 21 hours ago |
| 60 Minute Opening Range Breakout | about 21 hours ago |
| 10 DMA Resistance | about 21 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/07/2024
Oramed Pharmaceuticals Inc. Description
Oramed Pharmaceuticals, Inc., a pharmaceutical company, engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's products primarily comprise ORMD0801, an oral insulin capsule that is in Phase II clinical trials for the treatment of diabetes; and ORMD0901, an analog for GLP-1 gastrointestinal hormone that is in per-clinical trials. Its portfolio of product candidates is based on intellectual property that allows for the protection of proteins and polypeptides in the stomach, and for their absorption through the gastrointestinal wall. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Jerusalem, Israel.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Diabetes Medication Gastrointestinal Endocrine System Insulin Polyp Peptides Peptide Hormones Treatment Of Diabetes Glucagon Like Peptide 1 Integrated Security Tablet Pharmaceutical Solutions
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.67 |
| 52 Week Low | 2.0 |
| Average Volume | 96,090 |
| 200-Day Moving Average | 2.51 |
| 50-Day Moving Average | 2.37 |
| 20-Day Moving Average | 2.32 |
| 10-Day Moving Average | 2.30 |
| Average True Range | 0.09 |
| RSI (14) | 44.75 |
| ADX | 13.47 |
| +DI | 11.36 |
| -DI | 21.96 |
| Chandelier Exit (Long, 3 ATRs) | 2.15 |
| Chandelier Exit (Short, 3 ATRs) | 2.41 |
| Upper Bollinger Bands | 2.43 |
| Lower Bollinger Band | 2.21 |
| Percent B (%b) | 0.21 |
| BandWidth | 9.50 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.02 |
| MACD Histogram | -0.0087 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.32 | ||||
| Resistance 3 (R3) | 2.33 | 2.31 | 2.31 | ||
| Resistance 2 (R2) | 2.31 | 2.30 | 2.31 | 2.31 | |
| Resistance 1 (R1) | 2.29 | 2.29 | 2.28 | 2.28 | 2.30 |
| Pivot Point | 2.27 | 2.27 | 2.27 | 2.27 | 2.27 |
| Support 1 (S1) | 2.25 | 2.26 | 2.24 | 2.24 | 2.22 |
| Support 2 (S2) | 2.23 | 2.25 | 2.23 | 2.21 | |
| Support 3 (S3) | 2.21 | 2.23 | 2.21 | ||
| Support 4 (S4) | 2.20 |
